Does PRAX pay a dividend and is it safe?

Praxis Precision Medicines Inc. (PRAX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / PRAX / dividends

ALKS (78) AXSM (35) ABVX (54) ARWR (58) ⌘ Pro Terminal →

Praxis Precision Medicines Inc. (PRAX) Dividend Safety Gauge & 10-Year DRIP Compounder

$273.99 -4.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $271.41

Praxis Precision Medicines Inc. (PRAX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $7.98B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRAX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Praxis Precision Medicines Inc. (NASDAQ: PRAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $273.99 (-4.18% 1D, market cap $7.98B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PRAX ranks #283 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRAX compare to ALKS and AXSM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRAX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALKS (Alkermes plc) holds a B+ grade (78/100 RQD, P/E 31.5x, ROIC 14.0%, cap $7.61B) and AXSM (Axsome Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while ALKS leads on capital efficiency (14.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRAX?

▼

Per PRAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001689548), Praxis Precision Medicines Inc. generated $913.4M in revenue (+10578.8% YoY), -$303.0M in net income, and -$249.1M in free cash flow against $937.9M in total assets and $26.9M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $271.41 (-0.94%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRAX)Realized 20D OHLCV Swing Band: ±8.6%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY PRAX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (33% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)

20D Institutional Volume Accumulation (±8.6% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$239.02+7.3% Next Q

Q2 (-2Q)

Grade D$256.47+11.3% Next Q

Q3 (-1Q)

Grade D$285.48-4% Next Q

Current

Grade D$273.99-5.6% Hist 90D α

Trajectory: D (40) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRAX currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($296.31) and Max Pain ($287.69) forces dealer call-delta covering toward $412.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRAX)

✓Walkthrough of PRAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.84%📐 HORIZONTAL RANGE

2026-11-03O $288.6H $288.6L $274.0C $274.0VOL 306.6K

RES: $416.2SUP: $222.6SMA50: $296.3SMA200: $314.5

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRAX Butterfly Map → + Track PRAX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.5%/yr Implied 5Y Growth

vs. +10578.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRAX)

Health Care Rank #283 of 1015 ⚔️ ALKS vs PRAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRAX vs. ALKS, AXSM, ABVX, ARWR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Praxis Precision Medicines Inc. (PRAX) ranks #283 by composite RQD confidence (48/100, grade D) and #125 by equity capitalization ($7.98B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while ALKS leads on capital efficiency and profitability with 14.0% ROIC and 86.7% gross margin. ALKS currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with PRAX at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRAX ACTIVE Praxis Precision Medicines Inc.	D	48/100	—	—	-35.0%	-4.18%	$7.98B	Benchmark Subject
ALKS Alkermes plc	B+	78/100	31.5x	86.7%	14.0%	-0.99%	$7.61B	/alks-vs-prax →
AXSM Axsome Therapeutics Inc.	D-	35/100	—	—	-21.9%	-5.83%	$7.57B	/axsm-vs-prax →
ABVX Abivax SA	D+	54/100	32.8x	—	9.9%	-1.94%	$7.56B	/abvx-vs-prax →
ARWR Arrowhead Pharmaceuticals Inc.	D+	58/100	—	—	11.1%	-0.55%	$8.46B	/arwr-vs-prax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001689548 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Praxis Precision Medicines Inc. (PRAX) reported GAAP revenue of $913.4M (+10578.8% vs. FY2024 revenue of $8.6M , and +37225.5% cumulative change since FY2023) , GAAP net income of -$303.0M, operating cash flow of -$249.1M, and free cash flow of -$249.1M (-89.1% YoY). On the balance sheet, PRAX closed FY2025 with $937.9M in total assets against $26.9M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$913.4M	-$303.0M	-$249.1M	-$249.1M	$937.9M	$26.9M
FY2024 (FY)	2024-12-31	$8.6M	-$183.0M	-$131.8M	-$131.8M	$483.1M	$16.9M
FY2023 (FY)	2023-12-31	$2.4M	-$123.0M	-$111.1M	-$111.2M	$4.43B	$1.04B

3. PRAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRAX compare to ALKS and AXSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRAX?

Where is PRAX trading relative to its 50-day, 200-day, and 52-week technical levels?

PRAX last traded at $273.99 (-4.18% on volume of 312,389 shares), positioning the stock -7.53% below its 50-day simple moving average ($296.31) and -12.87% below its 200-day simple moving average ($314.46). Across its 52-week range of $154.45 to $392.70, PRAX sits at the 50.2% percentile with a 14-day RSI of 54.5 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($250.43 to $297.55).

Direct Sub-Reports: PRAX RQD Cockpit PRAX 12M Forecast PRAX Earnings & Move PRAX Dividends & DRIP PRAX Insiders & 13F PRAX Whale Options PRAX Profit Sankey PRAX News & Why

ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ SEC XBRL & RQD VERIFIED

PRAX — Praxis Precision Medicines Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Praxis Precision Medicines Inc. (PRAX) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $273.99 (-4.18% 1D, market capitalization $7.98B).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.09%.
Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (16/20): Incorporates a 0.91x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.03x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Praxis Precision Medicines Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..1B. Per the recent news wire, the company has two medicines under FDA review and is discussing launch readiness for them. Per the financials, FY 2025 revenue is — and FY 2024 revenue is $8.6M, indicating the company has not yet established a meaningful commercial revenue base. — for how these medicines are sold or to which customers.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Praxis Precision Medicines Inc. (PRAX) reported $913.4M in annual revenue (up from $8.6M in FY2024, +10578.8% YoY) and -$303.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.4M revenue, -$123.0M net income) through FY2025, PRAX scaled operating cash flow to -$249.1M and free cash flow to -$249.1M, backed by $937.9M in total assets against $26.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 48/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of -3.09% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $154.45 – $392.70 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 0.91x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the provided data.

Key Question #1: Can PRAX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $913.4M and free cash flow of -$249.1M, how will capital allocation balance growth reinvestment against $26.9M in total debt?
Key Question #3: How sensitive is PRAX's 33.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?

PRAX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Praxis Precision Medicines Inc. (PRAX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRAX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?

Yahoo Finance report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?

Yahoo Finance report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Praxis plans to discuss launch readiness for two medicines under FDA review.

Stock Titan report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Praxis Precision Medicines Stock In Focus As Investor Day Tests Launch Readiness

Simply Wall St report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Praxis Precision Medicine Q2 2026 Earnings Call Transcript

Benzinga report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Praxis Precision Medicines (NasdaqGS:PRAX) Stock Forecast & Analyst Predictions

Simply Wall St report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

UBS Initiates Praxis Precision Medicines at Buy With $706 Price Target

Yahoo Finance report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 2d ago

Praxis Precision Medicines stock sets November 12 Investor Day

ad-hoc-news.de report covering Praxis Precision Medicines Inc. (PRAX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRAX Bull vs. Bear Conversation Board — What's Your Call at $273.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRAX 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $343.12 (+20.0%)

📌 Pinned Debate

Forensic balance sheet scores 16/20 with Altman Z of 26 and Debt/Equity of 0.03, plus $357.3M cash, giving the company substantial runw

Long PRAX at $285.93 targeting $343.12. Forensic balance sheet scores 16/20 with Altman Z of 26 and Debt/Equity of 0.03, plus $357.3M cash, giving the company substantial runway against its losses.. Institutional whale score is 11/20 and the risk/reward vs. the $154.45 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — PRAX's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $220.17 (-23.0%)

Spot @ $285.93

ROIC of -35% and FCF yield of -3.09% leave the Fundamental Cash Engine at 7/20, with FY 2025 FCF of -$249.1M and no reported revenue.

Fading this rally in PRAX at $285.93. ROIC of -35% and FCF yield of -3.09% leave the Fundamental Cash Engine at 7/20, with FY 2025 FCF of -$249.1M and no reported revenue.. With a beta of 0.91 and the stock sitting at $285.93 (52-wk range $154.45–$392.70), the easy multiple expansion is already priced in.